ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?
Open Access
- 12 July 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 839997
Abstract
The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is frequently de-regulated in human cancer. Melanoma in particular exhibits a high incidence of activating BRAFV600E/K and NRASQ61L/K mutations and such cells are addicted to the activity of these mutant oncoproteins. As a result three different BRAF inhibitors (BRAFi) have now been approved for BRAFV600E/K- mutant melanoma and have transformed the treatment of this disease. Despite this, clinical responses are typically transient as tumour cells develop resistance. These resistance mechanisms frequently involve reinstatement of ERK1/2 signalling and BRAFi are now deployed in combination with one of three approved MEK1/2 inhibitors (MEKi) to provide more durable, but still transient, clinical responses. Furthermore, inhibitors to ERK1/2 (ERK1/2i) have also been developed to counteract ERK1/2 signalling. However, recent studies have suggested that BRAFi/MEKi and ERK1/2i resistance can arise through activation of a parallel signalling pathway leading to activation of ERK5, an unusual protein kinase that contains both a kinase domain and a transcriptional transactivation domain. Here we review the evidence supporting ERK5 as a mediator of BRAFi/MEKi and ERK1/2i resistance. We also review the challenges in targeting ERK5 signalling with small molecules, including paradoxical activation of the transcriptional transactivation domain, and discuss new therapeutic modalities that could be employed to target ERK5.Keywords
Funding Information
- Biotechnology and Biological Sciences Research Council
This publication has 86 references indexed in Scilit:
- Inhibition of Myc family proteins eradicates KRas-driven lung cancer in miceGenes & Development, 2013
- Mechanisms of acquired resistance to ERK1/2 pathway inhibitorsOncogene, 2012
- A Correction to the Research Article Titled: “Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells” by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. CookScience Signaling, 2011
- Alternative ERK5 regulation by phosphorylation during the cell cycleCellular Signalling, 2010
- Multisite phosphorylation of Erk5 in mitosisJournal of Cell Science, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in MicePLOS ONE, 2009
- The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transitionOncogene, 2007
- MAPK signalling: ERK5 versus ERK1/2EMBO Reports, 2006
- Primary Structure of BMK1: A New Mammalian MAP KinaseBiochemical and Biophysical Research Communications, 1995